Abstract: This invention relates to a detection system for detecting an analyte in a fluid medium. The detection system comprises a substrate that provides mechanical stability and is sized and shaped to intercept an infrared beam. A reactive material is coated on the substrate. When contacted with the analyte in the fluid medium, the reactive material reacts with the analyte and is altered. The detection system also comprises an infrared spectrometer producing the infrared beam that passes through the reactive material to a detector of the spectrometer. The alteration of the reactive material allows the spectrometer to identify and quantify the analyte. In one embodiment, the reactive material irreversibly reacts with the analyte. In another embodiment, the spectrometer is a non-ATR infrared spectrometer. In a further embodiment, the substrate is a disposable substrate.
Type:
Grant
Filed:
November 14, 2007
Date of Patent:
August 10, 2010
Assignee:
University Of Maine System Board Of Trustees
Abstract: A method to synthesize benzyl group protected alpha-pentagalloylglucose (?-PGG) and related compounds. The method comprises the steps of: suspending a highly reactive acylation agent and an acylating catalyst in a donor solvent; adding ?-D-glucose or an analogue thereof to the mixture; reacting the mixture at room temperature for a time sufficient for reaction to occur; evaporating the solvent; taking up the residue in an appropriate solvent; filtering the residue and solvent mixture; and evaporating off the solvent.
Abstract: Methods and compositions for synthesizing polymers, such as nucleic acids, are provided. Aspects of the invention include methods in which lipids and monomeric precursors, e.g., mononucleotides, of the desired polymeric products are combined to produce a reaction mixture. The reaction mixture is then subjected to one or more steps of drying and rehydrating to produce a desired polymeric product, e.g., nucleic acid. Also provided are the polymeric products themselves, e.g., nucleic acid products, as well as systems and kits for practicing embodiments of the invention.
Type:
Grant
Filed:
July 18, 2007
Date of Patent:
August 10, 2010
Assignee:
The Regents of the University of California
Abstract: The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.
Type:
Grant
Filed:
August 16, 2005
Date of Patent:
August 10, 2010
Assignee:
The Research Foundation of State University of New York
Inventors:
David G. Hangauer, Jr., Moustafa E. El-Araby, Karen L. Milkiewicz
Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, muscle wasting diseases and/or disorders, bone-related diseases and/or disorders, diabetes, cardiovascular disease, renal disease and others.
Type:
Grant
Filed:
April 16, 2007
Date of Patent:
August 10, 2010
Assignee:
University of Tennessee Research Foundation
Abstract: The invention relates to method of diagnosing Alzheimer's disease or detecting a predisposition to Alzheimer's disease including providing a test cell sample from a subject, exposing the test cell sample to labeled amyloid beta peptides, and determining the level of labeled amyloid beta peptides in the test cell sample, wherein lower levels of labeled amyloid beta peptides in the test cell sample compared to a control cell sample are indicative of Alzheimer's disease.
Type:
Grant
Filed:
October 19, 2007
Date of Patent:
August 10, 2010
Assignee:
The Regents of the University of California
Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
Type:
Grant
Filed:
August 16, 2002
Date of Patent:
August 10, 2010
Assignees:
Eli Lilly and Company, Washington University
Inventors:
David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
Abstract: The present invention is to provide a chicken LIF gene. Based on this genetic information, LIF protein derived from the chicken can be stably supplied and it solves the problems of the creation of transgenic chickens in the past. In addition, the present invention provides not only transgenic chickens for testing purposes but also supplies the first practical transgenic stock animals. The present invention relates to leukemia inhibitory factor (LIF) shown in sequence No. 2, and the gene that encodes thereof shown in sequence No. 1, and a manufacturing method of chicken LIF. In addition, the present invention pertains to a differential preventer of the chicken differentiable cell, and a method of chicken differential prevention and a culturing method for the chicken differentiable cell using thereof, and a medium comprising thereof.
Abstract: Isomaltooligosaccharides (IMOs) produced by Leuconostoc mesenteroides ATCC 13146 fermentation with a sucrose:maltose ratio of 2:1 have been discovered to be effective prebiotics in mixed cultures of microbial populations, including cultures from chicken ceca. Surprisingly in mixed microbial cultures this IMO composition proved as effective as FOS. Thus, these IMOs can be used as effective prebiotics for both birds and mammals. Moreover, the IMOs were discovered to be effective non-competitive inhibitors of ?-glucosidase. These IMOs also will be useful, as an ?-glucosidase inhibitor, in a therapeutic application for several diseases, including obesity, diabetes mellitus, pre-diabetes, gastritis, gastric ulcer, duodenal ulcer, caries, cancer, viral disease such as hepatitis B and C, HIV, and AIDS. A diet with 5-20% IMOs was also shown to reduce the abdominal fat tissue in mammals.
Type:
Grant
Filed:
September 27, 2007
Date of Patent:
August 10, 2010
Assignee:
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Abstract: A method for gene shuffling to form a mutant or chimeric gene, the method comprising: (a) assigning one or more segments of one or more genes based on regions of encoded amino acid sequence; (b) amplifying the one or more assigned segments of the gene using primers specific for each segment; and (c) causing recombination of the one or more amplified segments to form a mutant or chimeric gene. An oligonucleotide primer suitable for use in gene shuffling, the primer having a non-degenerate core based on a segment or template of a gene to be amplified, and the core being flanked by both 5? and 3? degenerate ends.
Type:
Grant
Filed:
August 29, 2001
Date of Patent:
August 10, 2010
Assignee:
Macquarie University
Inventors:
Moreland David Gibbs, Peter Leonard Bergquist, Kaisu Milja Helena Nevalainen
Abstract: The subject invention pertains to the therapeutic use of certain GAG-degrading enzymes, and enzyme combinations, to promote nerve repair and regeneration.
Type:
Grant
Filed:
January 31, 2005
Date of Patent:
August 10, 2010
Assignee:
Emory University
Inventors:
Arthur W. English, Robert McKeon, Erica Werner
Abstract: A self sustaining desalination system includes a chamber having a transparent inclined cover and a transparent bottom for receiving seawater or the like. The system includes a channel for conveying seawater to the chamber and a receptacle for receiving distillate at the base of the cover. The seawater is vaporized by solar energy passing through the incline cover and reflected up through the transparent bottom. A portion of the vaporized water condenses on the cooled inside cover and runs down into the receptacle. A second portion of the vaporized water is fed to the heat exchanger and condensed therein. In addition, a plurality of such systems are combined with a plurality of basic units each of which includes a wind turbine and an array of solar panels in a park like setting to provide electricity, drinking water and irrigation water for a small community.
Type:
Grant
Filed:
October 4, 2006
Date of Patent:
August 10, 2010
Assignee:
King Fahd University of Petroleum and Minerals
Inventors:
Ahmed Al-Garni, Farooq Saeed, Ayman Kassem
Abstract: Methods are described for mapping a pathway of differentiation of a population of embryonic cells that includes exposing the cells to an exogenous factor and measuring gene expression products that are characteristic of a particular cell type or lineage. Directing differentiation of human embryonic cells relies on dissociated embryoid bodies that are then exposed to one or more exogenous factors to enrich a culture for a particular cell type. The differentiated cells may be used for treating a medical condition in a human. Kits for determining differentiation pathways and screening exogenous factors for their utility in differentiation are provided.
Type:
Grant
Filed:
January 3, 2006
Date of Patent:
August 10, 2010
Assignee:
Yissum Research Development Company Of the Hebrew University of Jerusalem
Abstract: An apparatus capable of transporting a rider, specifically for an amusement ride. The apparatus is constructed in the form of a substantially hollow sphere which rides along the ground, which is preferably inclined, a track, or a predetermined path (being substantially flat but with guide rails or walls along its sides). An inner carriage, to which the rider's seat is attached, moves independently of the sphere and maintains a substantially constant attitude while the sphere rolls. The inner carriage can be formed in varying shapes such as a sphere, hemisphere, semicircle, tube or a circle.
Abstract: This invention relates to derivatives of hemiasterlin or Geodiamolide G having anti-mitotic activities and useful in treating cancer. These derivatives are represented by general formula I, wherein Y, n, R1, R2, R3, R6, R7, R70, R71, R72, R74, and R75 are as defined in the specification.
Type:
Grant
Filed:
July 21, 2008
Date of Patent:
August 10, 2010
Assignee:
University of British Columbia
Inventors:
Raymond Andersen, John Coleman, Dilip De Silva, Fangming Kong, Edward Piers, Debra Wallace, Michel Roberge, Theresa Allen
Abstract: A method for preparing titanium dioxide particles co-doped with nitrogen and fluorine includes the steps of: mixing boric acid with ammonium fluorotitanate in an aqueous medium to form ammonium oxotrifluorotitanate; liquid-phase depositing the ammonium oxotrifluorotitanate on a silicon-containing substrate; and thermo-treating the ammonium oxotrifluorotitanate on the silicon-containing substrate at a temperature ranging from 300 to 1000° C.
Abstract: The present invention provides a chroman compound of formula (I) and its pharmaceutical salt, methods of its preparation and its pharmaceutical applications. Wherein: X is O or S; n is for 2, 3 or 4; R1 is 6-substituted or 7-substituted halogen, C1-4alkyl, C1-4alkoxyl, benzyloxy, carbamoyl; R2 is nitrogen-containing five-membered or six-membered substituted heterocyclic ring selected from piperidinyl, morpholinyl, N-methyl-piperazinyl, N-(2-ethoxyl)piperazinyl, pyrrolyl, pyrazolyl or imidazolyl. The compounds are useful to prepare medicaments for treating cardiovascular diseases, their preparation employs mild reaction conditions, the raw material are plenty and easy to be obtained, and the operation and post-treatment in the preparation are simple.
Type:
Grant
Filed:
October 25, 2007
Date of Patent:
August 10, 2010
Assignee:
China Pharmaceutical University
Inventors:
Qidong You, Lvpei Du, Minyong Li, Lin Xia
Abstract: A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol.
Type:
Grant
Filed:
April 20, 2006
Date of Patent:
August 10, 2010
Assignee:
Ariel-University Research and Development Company Ltd.